Management of obesity in menopause: diet, exercise, pharmacotherapy and bariatric surgery.
Menopause is characterized by the progressive reduction of estrogens resulting to cessation of menses. It is associated with an increase of cardiovascular risk factors such as hyperglycemia, hypertension, dyslipidemia and of abdominal and/or selective visceral fat mass deposition. Obesity, a modern day epidemic, is promoted by an obesogenic environment that interacts with the genetic background. The result is a positive energy balance materialized by the accumulation of the adipose tissue. This process is marked by great individual variation. Obesity is also associated with the presence of cardiovascular risk factors. In this review, the main pathophysiologic processes for the increase of obesity in menopause and the possible effects of pre-menopausal obesity regarding the cessation of ovarian function are described. The interactions among the hypothalamic-pituitary-gonadal and -adrenal (stress system) axes and the environment are explored. Furthermore, the therapeutic means that a clinician can employ to help menopausal women to overcome the menopause-associated increase of their weight are developed.
Mastorakos
G
G
Endocrine Unit, 2nd University Department of Obstetrics & Gynaecology, Aretaieion Hospital, University of Athens Medical School, Athens, Greece. mastorakg@ath.forthnet.gr
Valsamakis
G
G
Paltoglou
G
G
Creatsas
G
G
D019440:Anti-Obesity Agents / Q000627:therapeutic use; D050110:Bariatric Surgery; D004038:Diet, Reducing; D015444:Exercise; D005260:Female; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000502:physiology; D008593:Menopause / Q000502:physiology*; D009765:Obesity / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*; D010913:Pituitary-Adrenal System / Q000502:physiology
D019440:Anti-Obesity Agents